Program
Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372
Its studies are mostly in Neoplasm Metastasis, led by NextPoint Therapeutics.
Furthest: phase 1, since Mar 30, 20261 company-led study, 1 open or runningNext primary completion: Apr 1, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NextPoint Therapeutics | 11 open or running | phase 1since Mar 30, 2026 | Mar 30, 2026 | Apr 1, 2027phase 1 · NCT07563829 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 30, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07563829 · 81 planned · United States
Ahead
- Apr 1, 2027Primary completion: phase 1 study in Neoplasm MetastasisNCT07563829
TargetBeta
“An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both HERV-H LTR-associating protein 2 (HHLA2; HHLA-2; B7 homolog 7; B7-H7) and T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07563829Neoplasm Metastasis · United States | 1 | Recruiting | Apr 1, 2027 | 81 |
How it is read
Names in the registry
- “NPX372”, 1 entry
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.